PIPE-791 Updated Nov 5
PIPE-791 is a mid-stage asset with no near-term binary catalyst; the next major event is the Phase 2 PROPEL-IPF readout estimated for mid-2028. The competitive landscape shifted significantly on October 12, 2026, when BMS's admilparant succeeded in Phase 3 for IPF, potentially becoming the first approved LPAR1 antagonist. Investors should watch for enrollment completion updates and whether Contineum can differentiate PIPE-791 on safety, dosing convenience, or CNS indications (chronic pain, MS) where BMS's compound may not compete.
- PIPE-791 targets a clinically validated mechanism (LPAR1 antagonism) in IPF, a disease with high unmet need affecting approximately 130,000 people in the US. The Phase 1b PET trial confirmed high brain receptor occupancy, and the Phase 1b chronic pain trial showed positive exploratory efficacy signals, supporting the drug's potential as a differentiated, once-daily oral therapy.
- The company has a strong cash position of $244.5 million as of September 30, 2026, providing runway through mid-2029, which funds the Phase 2 program and potential expansion without near-term dilution risk.
- Analyst consensus is Buy (6 buy, 3 hold) with a mean price target of $22.14, representing approximately 147% upside from the current $8.81 price. Multiple large institutional holders including BlackRock, Franklin Resources, and Balyasny have accumulated positions.
- Bristol Myers Squibb's admilparant (BMS-986278), a competing LPAR1 antagonist, succeeded in its Phase 3 ALOFT-IPF trial on October 12, 2026, meeting the primary endpoint at the 60 mg dose. BMS plans to file for regulatory approval, which could make admilparant the first approved LPAR1 antagonist for IPF and potentially limit PIPE-791's market opportunity.
- The Phase 2 PROPEL-IPF trial is not expected to read out until approximately June 2028, meaning there is no near-term binary catalyst for the stock. The stock has already fallen from its 52-week high of $17.79 to $8.81, reflecting the lack of near-term events and competitive pressure.
- Baird downgraded CTNM from Outperform to Neutral on October 14, 2026, and the stock dropped approximately 10% on November 5, 2026. The bull/bear evidence checklist shows a bearish net signal driven by elevated short-sale volume (z-score 2.06), analyst downgrade, insider sales via 10b5-1 plans, and several institutional exits including Baker Bros. and RA Capital.